Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension
Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension
复制标题
DOI：
10.1161/01.atv.0000168414.06853.f0
复制
发表时间：
2005-07-01
影响因子：
8.7
通讯作者：
Hoeper, MM
中科院分区：
文献类型：
--
作者：
Kielstein, JT;Bode-Böger, SM;Hoeper, MM
目的 - 我们探讨内源性 NO 合酶抑制剂不对称二甲基精氨酸 (ADMA) 在特发性肺动脉高压 (IPAH) 患者中的潜在作用。方法和结果 - 我们将 57 名 IPAH 患者的血浆 ADMA 水平与右心导管检查的心血管指标相关联。研究了 IPAH 患者生存的预测因素。此外，使用右心导管插入术在健康志愿者中研究了全身 ADMA 输注对肺心室阻力和每搏输出量的影响。 IPAH 患者的平均血浆 ADMA 浓度显着高于对照受试者（0.53 +/- 0.15 对比 0.36 +/- 0.05 mu mol/L；P
Objective-We explored the potential role of the endogenous NO synthase inhibitor asymmetrical dimethylarginine (ADMA) in patients with idiopathic pulmonary arterial hypertension (IPAH).Method and Results-We correlated plasma ADMA levels and cardiovascular indices from right heart catheterization in 57 patients with IPAH. Predictors of survival in patients with IPAH were studied. Furthermore, the effect of systemic ADMA infusion on pulmonary ventricular resistance and stroke volume was investigated in healthy volunteers using right heart catheterization. Mean plasma ADMA concentrations were significantly higher in patients with IPAH than in control subjects (0.53 +/- 0.15 versus 0.36 +/- 0.05 mu mol/L; P